Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects.

Donohoe G, Walters J, Morris DW, Quinn EM, Judge R, Norton N, Giegling I, Hartmann AM, Möller HJ, Muglia P, Williams H, Moskvina V, Peel R, O'Donoghue T, Owen MJ, O'Donovan MC, Gill M, Rujescu D, Corvin A.

Arch Gen Psychiatry. 2009 Oct;66(10):1045-54. doi: 10.1001/archgenpsychiatry.2009.139.

PMID:
19805695
2.

Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia.

Walters JT, Corvin A, Owen MJ, Williams H, Dragovic M, Quinn EM, Judge R, Smith DJ, Norton N, Giegling I, Hartmann AM, Möller HJ, Muglia P, Moskvina V, Dwyer S, O'Donoghue T, Morar B, Cooper M, Chandler D, Jablensky A, Gill M, Kaladjieva L, Morris DW, O'Donovan MC, Rujescu D, Donohoe G.

Arch Gen Psychiatry. 2010 Jul;67(7):692-700. doi: 10.1001/archgenpsychiatry.2010.81.

PMID:
20603450
3.

Association between the dysbindin gene (DTNBP1) and cognitive functions in Japanese subjects.

Hashimoto R, Noguchi H, Hori H, Ohi K, Yasuda Y, Takeda M, Kunugi H.

Psychiatry Clin Neurosci. 2009 Aug;63(4):550-6. doi: 10.1111/j.1440-1819.2009.01985.x. Epub 2009 May 22.

5.

The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up.

Walters JT, Rujescu D, Franke B, Giegling I, Vásquez AA, Hargreaves A, Russo G, Morris DW, Hoogman M, Da Costa A, Moskvina V, Fernández G, Gill M, Corvin A, O'Donovan MC, Donohoe G, Owen MJ.

Am J Psychiatry. 2013 Aug;170(8):877-85. doi: 10.1176/appi.ajp.2013.12020226.

PMID:
23903335
6.

Variability in working memory performance explained by epistasis vs polygenic scores in the ZNF804A pathway.

Nicodemus KK, Hargreaves A, Morris D, Anney R, Gill M, Corvin A, Donohoe G; Schizophrenia Psychiatric Genome-wide Association Study (GWAS) Consortium.; Wellcome Trust Case Control Consortium 2..

JAMA Psychiatry. 2014 Jul 1;71(7):778-85. doi: 10.1001/jamapsychiatry.2014.528.

7.

A functional promoter polymorphism of neuronal nitric oxide synthase moderates prefrontal functioning in schizophrenia.

Reif A, Schecklmann M, Eirich E, Jacob CP, Jarczok TA, Kittel-Schneider S, Lesch KP, Fallgatter AJ, Ehlis AC.

Int J Neuropsychopharmacol. 2011 Aug;14(7):887-97. doi: 10.1017/S1461145710001677. Epub 2011 Feb 1.

PMID:
21281558
8.

Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms.

Begemann M, Grube S, Papiol S, Malzahn D, Krampe H, Ribbe K, Friedrichs H, Radyushkin KA, El-Kordi A, Benseler F, Hannke K, Sperling S, Schwerdtfeger D, Thanhäuser I, Gerchen MF, Ghorbani M, Gutwinski S, Hilmes C, Leppert R, Ronnenberg A, Sowislo J, Stawicki S, Stödtke M, Szuszies C, Reim K, Riggert J, Eckstein F, Falkai P, Bickeböller H, Nave KA, Brose N, Ehrenreich H.

Arch Gen Psychiatry. 2010 Sep;67(9):879-88. doi: 10.1001/archgenpsychiatry.2010.107. Erratum in: Arch Gen Psychiatry. 2010 Oct;67(10):1077.

PMID:
20819981
9.

A NOS1 variant implicated in cognitive performance influences evoked neural responses during a high density EEG study of early visual perception.

O'Donoghue T, Morris DW, Fahey C, Da Costa A, Foxe JJ, Hoerold D, Tropea D, Gill M, Corvin A, Donohoe G.

Hum Brain Mapp. 2012 May;33(5):1202-11. doi: 10.1002/hbm.21281. Epub 2011 Apr 21.

PMID:
21520349
10.

Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

Nicodemus KK, Law AJ, Radulescu E, Luna A, Kolachana B, Vakkalanka R, Rujescu D, Giegling I, Straub RE, McGee K, Gold B, Dean M, Muglia P, Callicott JH, Tan HY, Weinberger DR.

Arch Gen Psychiatry. 2010 Oct;67(10):991-1001. doi: 10.1001/archgenpsychiatry.2010.117.

11.

Evidence of IQ-modulated association between ZNF804A gene polymorphism and cognitive function in schizophrenia patients.

Chen M, Xu Z, Zhai J, Bao X, Zhang Q, Gu H, Shen Q, Cheng L, Chen X, Wang K, Deng X, Ji F, Liu C, Li J, Dong Q, Chen C.

Neuropsychopharmacology. 2012 Jun;37(7):1572-8. doi: 10.1038/npp.2012.1. Epub 2012 Feb 29.

12.

Evidence for the contribution of NOS1 gene polymorphism (rs3782206) to prefrontal function in schizophrenia patients and healthy controls.

Zhang Z, Chen X, Yu P, Zhang Q, Sun X, Gu H, Zhang H, Zhai J, Chen M, Du B, Deng X, Ji F, Wang C, Xiang Y, Li D, Wu H, Li J, Dong Q, Chen C.

Neuropsychopharmacology. 2015 May;40(6):1383-94. doi: 10.1038/npp.2014.323. Epub 2014 Dec 10.

13.

RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample.

Prasad KM, Almasy L, Gur RC, Gur RE, Pogue-Geile M, Chowdari KV, Talkowski ME, Nimgaonkar VL.

Schizophr Bull. 2010 Sep;36(5):983-90. doi: 10.1093/schbul/sbp002. Epub 2009 Mar 12.

14.

Effects of a novel schizophrenia risk variant rs7914558 at CNNM2 on brain structure and attributional style.

Rose EJ, Hargreaves A, Morris D, Fahey C, Tropea D, Cummings E, Caltagirone C, Bossù P, Chiapponi C, Piras F, Spalletta G, Gill M, Corvin A, Donohoe G.

Br J Psychiatry. 2014 Feb;204(2):115-21. doi: 10.1192/bjp.bp.113.131359. Epub 2013 Dec 5. Erratum in: Br J Psychiatry. 2015 Feb;206(2):169.

15.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
16.

No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population.

Okumura T, Okochi T, Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Tsunoka T, Ujike H, Inada T, Ozaki N, Iwata N.

Neuromolecular Med. 2009;11(2):123-7. doi: 10.1007/s12017-009-8068-z. Epub 2009 Jun 10.

PMID:
19513863
17.

MAP1B and NOS1 genes are associated with working memory in youths with attention-deficit/hyperactivity disorder.

Salatino-Oliveira A, Wagner F, Akutagava-Martins GC, Bruxel EM, Genro JP, Zeni C, Kieling C, Polanczyk GV, Rohde LA, Hutz MH.

Eur Arch Psychiatry Clin Neurosci. 2016 Jun;266(4):359-66. doi: 10.1007/s00406-015-0626-9. Epub 2015 Aug 2.

PMID:
26233433
18.

Neuropsychological effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253.

Donohoe G, Walters J, Hargreaves A, Rose EJ, Morris DW, Fahey C, Bellini S, Cummins E, Giegling I, Hartmann AM, Möller HJ, Muglia P, Owen MJ, Gill M, O'Donovan MC, Tropea D, Rujescu D, Corvin A.

Genes Brain Behav. 2013 Mar;12(2):203-9. doi: 10.1111/gbb.12016.

19.

The NOS1 variant rs6490121 is associated with variation in prefrontal function and grey matter density in healthy individuals.

Rose EJ, Greene C, Kelly S, Morris DW, Robertson IH, Fahey C, Jacobson S, O'Doherty J, Newell FN, McGrath J, Bokde A, Garavan H, Frodl T, Gill M, Corvin AP, Donohoe G.

Neuroimage. 2012 Mar;60(1):614-22. doi: 10.1016/j.neuroimage.2011.12.054. Epub 2011 Dec 29.

PMID:
22227051
20.

Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder.

Meltzer HY, Brennan MD, Woodward ND, Jayathilake K.

Schizophr Res. 2008 Dec;106(2-3):258-64. doi: 10.1016/j.schres.2008.08.029. Epub 2008 Sep 27.

PMID:
18823757

Supplemental Content

Support Center